Development of Anticandidal Delivery Systems: (II) Mucoadhesive Devices for Prolonged Drug Delivery in the Oral Cavity

Conventional dosage forms designed for drug delivery in the oral cavity suffer from the disadvantage of an initial burst of activity followed by a rapid decrease in concentration to subtherapeutic levels. To counter this effect, two prolonged-release dosage forms were devised for the treatment of oral candidiasis. These devices were to contain the antifungals, chlorhexidine and clotrimazole, for therapy against Candida albicans, and also benzocaine and hydrocortisone to combat the pain and inflammation secondaly to a candidal infection. Release studies demonstrated that only chlorhexidine and clotrimazole could be delivered in a controlled manner from the mucoadhesive patches. On the other hand, release of all four drugs could be controlled from the mucoadhesive tablets, with optimum release of the drugs in 24 hr achieved using sodium carboxymethylcellulose and polyethylene oxide (85:15) combination tablets.     

Effect of Hydrotropic Substances on the Complexation of Clotrimazole with β-Cyclodextrin

The phase diagrams of clotrimazole/β-cyclodextrin (β-CD) in phosphate buffer, pH = 7.1, containing 0.5 M of various hydrotropic agents were constructed. The water structure disruptors, urea and nicotinamide, increased the intrinsic solubility of the antimycotic drug clotrimazole while the water structure forming agents, sorbitol and fructose, decreased the solubility. Concerning the complex constant between clotrimazole and β-CD, it was the other way around. The connection between the slopes of the phase diagrams, the intrinsic solubility of clotrimazole and the complex constant was discussed. Nicothamide decreased the solubility of β-CD in the buffer solution. The results reported in this study are in disagreement with the claim that addition of water structure forming agents to cyclodextrin solutions can be used to increase the total solubility of drugs     

Formulation Compatibility of Myristyl Nicotinate with Drugs Used to Treat Dermatological Conditions Involving an Impaired Skin Barrier

A number of dermatology conditions including skin photodamage, atopic dermatitis, and rosacea involve skin barrier impairment and first line therapies for these conditions including retinoids and steroids further impair skin barrier function. We have evaluated the compatibility of myristyl nicotinate, an agent that enhances skin barrier function, with drugs used to treat conditions where skin barrier impairment is present including photodamage (retinoic acid), atopic dermatitis (hydrocortisone, triamcinolone acetonide), rosacea (metronidazole), and seborrheic dermatitis (ketoconazole). Myristyl nicotinate was found to be compatible with each of the drugs examined when formulated together and also was shown to be photocompatible with retinoic acid. Our results suggest that the combination of myristyl nicotinate with these drugs is a feasible therapeutic development strategy.     

Formulation compatibility of myristyl nicotinate with drugs used to treat dermatological conditions involving an impaired skin barrier

A number of dermatology conditions including skin photodamage, atopic dermatitis, and rosacea involve skin barrier impairment and first line therapies for these conditions including retinoids and steroids further impair skin barrier function. We have evaluated the compatibility of myristyl nicotinate, an agent that enhances skin barrier function, with drugs used to treat conditions where skin barrier impairment is present including photodamage (retinoic acid), atopic dermatitis (hydrocortisone, triamcinolone acetonide), rosacea (metronidazole), and seborrheic dermatitis (ketoconazole). Myristyl nicotinate was found to be compatible with each of the drugs examined when formulated together and also was shown to be photocompatible with retinoic acid. Our results suggest that the combination of myristyl nicotinate with these drugs is a feasible therapeutic development strategy.     

Investigation of the antibacterial activity and efflux pump inhibitory effect of co-loaded piperine and gentamicin nanoliposomes in methicillin-resistant Staphylococcus aureus

Objective: Antibiotic resistance has stimulated the research for developing novel strategies that can prevent bacterial growth. Methicillin-resistant Staphylococcus aureus (MRSA), regarded as one of the most serious antibiotic-resistant bacteria which has been conventionally recognized as a nosocomial pathogen.

Materials and methods: Nanoliposomal formulations of piperine and gentamicin were prepared by dehydration-rehydration (DRV) method and characterized for size, zeta potential and encapsulation efficiency. Antibactericidal activities of liposomal and free forms were evaluated against MRSA ATCC 43300 by the determination of minimum inhibitory concentration (MIC), minimum bactericidal concentration (MBC) and fractional inhibitory concentration index (FICI). The time-kill studies were carried out to evaluate the potency of antibacterial agents. The effect of piperine on bacterial efflux pumps was also investigated.

Results: MIC values of gentamicin and piperine were 32 and 100?µg/mL, respectively. Synergetic effects were observed by the combination of gentamicin and piperine and FICI was determined to be 0.5. Following incorporation of gentamicin into liposomal gentamicin and liposomal combination, the MIC values were reduced 16- and 32-fold, respectively. MBC values of gentamicin reduced 4 and 8 times following incorporation into gentamicin and combination liposomes, respectively. In comparison with vancomycin, liposomal combination was more effective in bacterial inhibition and killing. Liposomal combination was the most effective preparations in time-kill study. Our findings indicated that liposomal piperine was able to inhibit the efflux pump sufficiently.

Conclusion: The results of this study revealed that liposomal combination is a powerful nano-antibacterial agent to eradicate MRSA infection. This dual-loaded formulation was an effective approach for eradication of MRSA.     

Sugars as solid dispersion carrier to improve solubility and dissolution of the BCS class II drug: clotrimazole

Solid dispersion of poorly soluble BCS class II drug, clotrimazole, was prepared with the aim of enhancing its dissolution profile. Solid dispersions were prepared using various sugars as carriers at different weight ratio to drug-like d-mannitol, d-fructose, d-dextrose and d-maltose by fusion method. The solubility of plain clotrimazole in different percent of sugar solutions was measured. Also, its solubility in solid dispersion and their physical mixture were assessed. The dissolution of all the prepared SD tablets, direct compressed clotrimazole tablet and plain drug were tested using the U.S. Pharmacopeia convention (USP) apparatus II. The dissolution profiles were characterized by parameters like area under curve (AUC), mean residence time (MRT), mean dissolution time (MDT) and percent dissolution efficiency (% DE). The release kinetics study was performed using DD Solver TM software. The selected solid dispersions (SDs) were evaluated for antifungal activity. A 100% solution of mannitol showed 806-fold increases in solubility as compared with plain clotrimazole in water. It was observed that the dissolution profile of clotrimazole was improved by mannitol SD at drug to sugar ration of 1:3. The percent DE value for mannitol SD tablet was found to be 77.3516% as against plain drug and directly compressed tablet of clotrimazole at 50.9439% and 31.33%, respectively. Also the antifungal activity indicated by inhibition zone was found to be 54?mm indicating enhance activity against Candida albicans as compared with plain CTZ at 6.6?mm. Thus, it can be concluded that the sugar alcohol, that is, mannitol is a more promising hydrophilic carrier for solid dispersion preparation to improve the solubility and dissolution of poorly soluble drugs.     

Preparation,in Vitro and in Vivo Evaluation of Liposomal/Niosomal Gel Delivery Systems for Clotrimazole

Clotrimazole, which is an imidazole derivative antifungal agent, was widely used for the treatment of mycotic infections of the genitourinary tract. To develop alternative formulation for the vaginal administration of clotrimazole to provide sustained and controlled release of appropriate drug for local vaginal therapy, liposomes/niosomes were evaluated as delivery vehicles. To optimize the preparation of liposomes/niosomes with regard to size and entrapment efficiency, multilamellar liposomes/niosomes containing drug were prepared by lipid hydration method. The prepared liposomes/niosomes were incorporated into 2% carbopol gel, and the systems were evaluated for drug stability in phosphate-buffered saline (pH 7.4) and simulated vaginal fluid at 37 ± 1°C. Further, the vesicle gel system was evaluated by antifungal activity and tolerability on tissue level in rat.     

Preparation, in vitro and in vivo evaluation of liposomal/niosomal gel delivery systems for clotrimazole

Clotrimazole, which is an imidazole derivative antifungal agent, was widely used for the treatment of mycotic infections of the genitourinary tract. To develop alternative formulation for the vaginal administration of clotrimazole to provide sustained and controlled release of appropriate drug for local vaginal therapy, liposomes/niosomes were evaluated as delivery vehicles. To optimize the preparation of liposomes/niosomes with regard to size and entrapment efficiency, multilamellar liposomes/niosomes containing drug were prepared by lipid hydration method. The prepared liposomes/niosomes were incorporated into 2% carbopol gel, and the systems were evaluated for drug stability in phosphate-buffered saline (pH 7.4) and simulated vaginal fluid at 37 +/- 1 degrees C. Further, the vesicle gel system was evaluated by antifungal activity and tolerability on tissue level in rat.     

Preparation, in Vitro and in Vivo Evaluation of Liposomal/Niosomal Gel Delivery Systems for Clotrimazole

Clotrimazole, which is an imidazole derivative antifungal agent, was widely used for the treatment of mycotic infections of the genitourinary tract. To develop alternative formulation for the vaginal administration of clotrimazole to provide sustained and controlled release of appropriate drug for local vaginal therapy, liposomes/niosomes were evaluated as delivery vehicles. To optimize the preparation of liposomes/niosomes with regard to size and entrapment efficiency, multilamellar liposomes/niosomes containing drug were prepared by lipid hydration method. The prepared liposomes/niosomes were incorporated into 2% carbopol gel, and the systems were evaluated for drug stability in phosphate-buffered saline (pH 7.4) and simulated vaginal fluid at 37 ± 1°C. Further, the vesicle gel system was evaluated by antifungal activity and tolerability on tissue level in rat.     

Influence of drug lipophilicity on terpenes as transdermal penetration enhancers.

Percutaneous absorption-enhancing effects on the skin of hairless mice of 11 monoterpenes [1, (+)-limonene; 2, (-)-menthone; 3, (+)-terpinen-4-ol; 4, alpha-terpineol; 5, 1,8-cineole; 6, (+)-carvone; 7, (-)-verbenone; 8, (-)-fenchone; 9, p-cymene; 10, (+)-neomenthol; and 11, geraniol] were investigated using three different model drugs (caffeine, hydrocortisone, triamcinolone acetonide [TA]) with varying lipophilicities. Terpenes were applied at 0.4 M in propylene glycol (PG) to mouse skin. The model drugs were applied as suspensions in PG 1 hr following enhancer pretreatment. The combination of terpenes in PG provided significant enhancement of the permeation of caffeine through mouse skin. The most active compounds 10 and 11 increased permeation by between 13-fold and 16-fold. The terpenes also enhanced the delivery of hydrocortisone, but not to as great an extent. The most active compounds 3 and 4 increased permeation between 3.9-fold and 5-fold. The compounds examined did not significantly increase the delivery of TA. The most active compound 4 only increased delivery 2.5-fold, while the next most active compound 6 only increased delivery 1.7-fold. Overall, these results indicate that the combination of terpenes with PG can significantly increase the transdermal penetration of the hydrophilic drug caffeine and the polar steroid hydrocortisone.     

Development of a topical suspension containing three active ingredients

The objective of this study was to develop a topical suspension that contains sarafloxacin hydrochloride (1 mg/mL), triamcinolone acetonide (1 mg/mL), and clotrimazole (10 mg/mL), and is stable at room temperature (15-28°C) for clinical usage. Due to the difference in the physicochemical properties and chemical stability profiles of these three active ingredients, it is a challenge to develop a stable suspension formulation containing these three drugs. In this study, the stability of these drugs in different buffer solutions was determined under different accelerated isothermal conditions. The Arrhenius equation was subsequently utilized to predict the room-temperature stability of these three drugs in these buffer solutions. By knowing the room-temperature solubility of the drugs in the buffer solution, the stability of the drugs in suspension was predicted. As a result, a 0.02 M phosphate buffer (pH 7.0) containing 0.02% (w/v)polysorbate 20, 1% (w/v) NaCl, and 0.1% (w/v) EDTA was determined to be an acceptable medium. In addition, 0.35% (w/v) high-viscosity carboxymethylcellulose (HV-CMC) was first selected as the suspending agent to enhance the redispersibility of the suspension. Stability data further supported that all three drugs were stable in the suspension containing HV-CMC with less than 5% potency loss for at least 6 months at 40°C and 12 months at 25°C. However, the viscosity drop of this HV-CMC formulation at 25°C and 40°C became a product stability concern. To improve the viscosity stability of the suspension, the medium-viscosity carboxymethylcellulose (MV-CMC) was selected to replace the HV-CMC as the suspending agent. The optimal combination of MV-CMC and sodium chloride in achieving the most desirable dispersion properties for the formulation was determined through the use of a 3² factorial design. The optimal formulation containing 1% MV-CMC and 1% sodium chloride has shown improved viscosity stability during storage and has been used for clinical studies.     

Effectiveness of barrier film with a cellulose coating that carries nisin blends for the inhibition of listeria monocytogenes

The objective of this study was to determine the effectiveness of two nisin blend antimicrobial agents (Guardian NR 250, Novagard CBI) incorporated into a cellulose coating that was applied onto a barrier film against Listeria monocytogenes. The minimum inhibitory concentration (MIC) of the agents in solution against L. monocytogenes was found to be 2.74 mg/ml for the two nisin blends. The concentrations tested for both nisin blend treatments were 5.49, 10.9, 16.4 and 21.9 mg/ml. Guardian NR 250 resulted in wider zones of inhibition compared to the Novagard CBI at all levels tested. The MIC for Guardian NR 250 in the film was 5.49 mg/ml. Films containing Novagard CBI did not show any antimicrobial activity. A food challenge study was conducted using the film containing Guardian NR 250 at levels of 5.49 and 21.9 mg/ml. Inoculated fresh beef cubes were individually packaged with pre‐made barrier film pouches that had an interior cellulose coating containing the antimicrobial agent and stored at 4°C for 36 days. Bacterial colonies were enumerated every 6 days on modified Oxford agar. There was no significant difference in the L. monocytogenes population between two levels of Guardian NR 250 throughout the study. There was statistically significant inhibition of L. monocytogenes for both levels of Guardian NR 250 during 18–30 days of storage compared to a control film without the antimicrobial agent. Copyright © 2010 John Wiley & Sons, Ltd.     

Niosomes as a potential drug delivery system for increasing the efficacy and safety of nystatin

Nonionic surfactant (NIS) vesicles (niosomes) formed from self-assembly of hydrated synthetic NIS monomers are capable of entrapping a variety of drugs and have been evaluated as an alternative to liposomes. Nystatin (NYS) is a polyene antifungal drug that has been used in the treatment of cutaneous, vaginal and oral fungal infections since the 1950s. The aim of this work is to encapsulate NYS in niosomes to obtain a safe and effective formula administered parenterally for neutropenic patients. NYS niosomes were prepared by the thin-film hydration method using Span 60 or Span 40 and cholesterol (CHOL). Stearylamine and dicetyl phosphate were added as the positive and negative charge-inducing agents (CIA), respectively. Two molar ratios were used, namely NIS/CHOL/CIA (1:1:0.1 and 2:1:0.25). Neutral and positively charged niosomes gave the highest encapsulation efficiencies. NYS niosomes were characterized using transmission electron microscopy, differential scanning calorimetry and dynamic light scattering. The release of neutral and negatively charged NYS niosomes was estimated, and it showed a slow sustained release profile. A 25-kGy γ-irradiation dose was sufficient to sterilize the investigated vesicles. NYS niosomes exerted less nephrotoxicity and hepatotoxicity in vivo, showed higher level of drug in vital organs and revealed pronounced efficacy in elimination of the fungal burden in experimental animals infected with Candida albicans compared with those treated with free NYS. Niosomal encapsulation thus provided means for parenteral administration of NYS, reducing its toxicity and making it a more active antifungal agent.     

EVA copolymer matrix for intra-oral delivery of antimicrobial and antiviral agents

Biocompatible ethylene vinyl acetate copolymer (EVA) was utilized to study the release of an antiviral drug (acyclovir (ACY)) and an antimicrobial drug (doxycycline hyclate (DOH)). Release of both drugs from EVA was measured individually and in combination. The effect of drug combination of DOH and ACY is presented. Additionally, the release rate of DOH after coating of the matrix with a different copolymer, in drug-loading with increasing loads of DOH, and with increases in temperature are also presented. The drugs incorporated in EVA films were prepared from the dry sheet obtained by solvent evaporation of polymer casting solutions with drugs. Drug release from the films was examined for about 12 days in distilled water at 37 °C. Changes in optical density were followed spectrophotometrically. The combination of ACY and DOH resulted in an increased release of ACY by about three times (P < 0.001) while DOH showed a decrease in rate of about two times compared to the individual release rates (P = 0.008). Increases in drug levels of DOH resulted in increases in drug release rates (P = 0.001). The release rate of DOH increased with temperature (P = .001; 27, 32, 37 and 42 °C were studied) and the energy of activation (ΔE ^≠ = 56.69 kJ/mol) was calculated using the Arrhenius equation for the diffusion of DOH molecules. Thus, the release rates of drugs were influenced by many factors: drug combination, coating the device, drug-loading, and temperature variation. Therefore it is proposed that controlling these variables should make it possible to obtain therapeutic levels of drugs released from drug loaded polymer, which may be beneficial in treating oral infections.     

Niosomes as a potential drug delivery system for increasing the efficacy and safety of nystatin

Nonionic surfactant (NIS) vesicles (niosomes) formed from self-assembly of hydrated synthetic NIS monomers are capable of entrapping a variety of drugs and have been evaluated as an alternative to liposomes. Nystatin (NYS) is a polyene antifungal drug that has been used in the treatment of cutaneous, vaginal and oral fungal infections since the 1950s. The aim of this work is to encapsulate NYS in niosomes to obtain a safe and effective formula administered parenterally for neutropenic patients. NYS niosomes were prepared by the thin-film hydration method using Span 60 or Span 40 and cholesterol (CHOL). Stearylamine and dicetyl phosphate were added as the positive and negative charge-inducing agents (CIA), respectively. Two molar ratios were used, namely NIS/CHOL/CIA (1:1:0.1 and 2:1:0.25). Neutral and positively charged niosomes gave the highest encapsulation efficiencies. NYS niosomes were characterized using transmission electron microscopy, differential scanning calorimetry and dynamic light scattering. The release of neutral and negatively charged NYS niosomes was estimated, and it showed a slow sustained release profile. A 25-kGy γ-irradiation dose was sufficient to sterilize the investigated vesicles. NYS niosomes exerted less nephrotoxicity and hepatotoxicity in vivo, showed higher level of drug in vital organs and revealed pronounced efficacy in elimination of the fungal burden in experimental animals infected with Candida albicans compared with those treated with free NYS. Niosomal encapsulation thus provided means for parenteral administration of NYS, reducing its toxicity and making it a more active antifungal agent.     

Formulation and evaluation of clotrimazole transdermal spray

Context: Transdermal spray (TS) of clotrimazole (CTZ) was formulated to improve the drug transport through the skin up to 12?h to achieve the antifungal efficacy.

Objective: The aim of present study was to formulate and evaluate antifungal transdermal spray to improve the permeation of clotrimazole across the skin and to decrease the dosing frequency in fungal infection.

Materials and methods: Different ratios of ethanol and acetone and various grades of eudragit and ethyl cellulose were evaluated according to six criteria: viscosity, drying time, stickiness, appearance and integrity on skin and water washability. Propylene glycol (PG) and polyethylene glycol 400 (PEG 400) were used in the study as plasticizer and solubilizer. The TS was evaluated for in vitro drug release, spray angle, spray pattern, average weight per dose, pH, drug content, evaporation time, leak test and antifungal efficacy study.

Results and discussion: Eudragit E100 and blend of ethanol and acetone (80:20) satisfied the desired criteria. The selection of optimized batch was based on the results of in vitro drug release, spray pattern and spray angle. The optimized batch showed the spray angle <85° and uniform spray pattern. The formulation containing PG showed higher drug release than PEG 400. The inclusion of eutectic mixture consisting of camphor and menthol (1:1) showed improved drug transport through the rat skin and larger mean zone of inhibition indicating the improved antifungal efficacy.

Conclusion: The TS of CTZ can be an innovative and promising approach for the topical administration in the fungal diseases.     

Efficacy of biogenic silver nanoparticles against clinical isolates of fungi causing mycotic keratitis in humans

Mycotic keratitis is mainly responsible for vision loss caused by various fungi. Sometimes, proper treatment of such infection is not possible due to unavailability of effective antifungal agents and development of resistance of such fungi to antimycotic drugs. Hence, it is necessary to search for potential antifungal agents, which can effectively eradicate fungal infection of eyes. Nanoparticles‐based antifungal drugs overcome this problem by increasing permeability and properties of drug molecules. In the present study, silver nanoparticles were synthesised by using Helminthosporium sp. and Chaetomium sp. following sequential reduction technique. The synthesised silver nanoparticles were detected primarily by UV‐visible spectrophotometer showing absorption spectra at 424 and 433 nm, respectively. Nanoparticles tracking analysis confirmed the mean particle size of silver nanoparticles as 45 and 55 nm. The synthesised AgNPs showed significant antifungal activity against fungi causing mycotic keratitis, when used alone and in combination with ketoconazole and amphotericin B in the range of 30–70 microgram per millilitre of minimum inhibitory concentration. Thus, the synthesised AgNPs can be used to enhance the activities of ketoconazole and amphotericin B.Inspec keywords: silver, nanoparticles, nanomedicine, antibacterial activity, diseases, permeability, ultraviolet spectra, visible spectra, particle sizeOther keywords: biogenic silver nanoparticles, fungi, mycotitic keratitis, vision loss, infection, antifungal agents, antimycotic drugs, antifungal drugs, permeability, Helminthosporium sp, Chaetomium sp, sequential reduction technique, UV‐visible spectrophotometer, mean particle size, ketoconazole, amphotericin B, wavelength 424 nm, wavelength 433 nm, size 45 nm, size 55 nm, Ag     

Microemulsion for simultaneous transdermal delivery of benzocaine and indomethacin: in vitro and in vivo evaluation

This study investigated simultaneous transdermal delivery of indomethacin and benzocaine from microemulsion. Eucalyptus oil based microemulsion was used with Tween 80 and ethanol being employed as surfactant and cosurfactant, respectively. A microemulsion formulation comprising eucalyptus oil, polyoxyethylene sorbitan momooleate (Tween 80), ethanol and water (20:30:30:20) was selected. Indomethacin (1% w/w) and benzocaine (20% w/w) were incorporated separately or combined into this formulation before in vitro and in vivo evaluation. Application of indomethacin microemulsion enhanced the transdermal flux and reduced the lag time compared to saturated aqueous control. The same trend was evident for benzocaine microemulsion. Simultaneous application of the two drugs in microemulsion provided similar enhancement pattern. The in vivo evaluation employed the pinprick method and revealed rapid anesthesia after application of benzocaine microemulsion with the onset being 10?min and the action lasting for 50?min. For indomethacin microemulsion, the analgesic effect was recorded after 34.5?min and lasted for 70.5?min. Simultaneous application of benzocaine and indomethacin provided synergistic effect. The onset of action was achieved after 10?min and lasted for 95?min. The study highlighted the potential of microemulsion formulation in simultaneous transdermal delivery of two drugs.     

Formulation development and stability studies of aqueous metronidazole benzoate suspensions containing various suspending agents

Metronidazole is a synthetic antibacterial and antiprotozoan agent. Crystallization occurs in aqueous metronidazole benzoate suspensions caused by an anhydrate to monohydrate conversion. This study aimed to develop an aqueous metronidazole benzoate suspension that does not exhibit this hydration and the accompanying crystal growth. Four suspending agent systems were evaluated. Xanthan gum and Avicel® RC-591 (a combination of microcrystalline cellulose and carboxymethylcellulose sodium) were found to be the suspending agents that resulted in optimal formulation properties. Monohydrate formation did not occur in product containing Avicel® RC-591, indicating that suspending agents may exert a positive effect on metronidazole benzoate suspension stability.     

Comparative study of antifungal effect of green and chemically synthesised silver nanoparticles in combination with carbendazim,mancozeb, and thiram

This study reports synthesis and characterisation of silver nanoparticles and their effect on antifungal efficacy of common agricultural fungicides. Silver nanoparticles were synthesised using biological and chemical reduction methods employing Elettaria cardamomum leaf extract and sodium citrate, respectively. Nanoparticles were then characterised using UV–Visible spectroscopy, X‐ray diffraction (XRD), transmission electron microscopy, and dynamic light scattering (DLS). While XRD assigned particles size of 31.86 nm for green and 41.91 nm for chemical silver nanoparticles with the help of the Debye–Scherrer formula, DLS specified monodisperse nature of both suspensions. Nanoparticles were tested individually and in combination with fungicides (carbendazim, mancozeb, and thiram) against fungal phytopathogens. Silver nanoparticles exhibited good antifungal activity and minimum inhibitory concentration (MIC) was observed in the range of 8–64 µg/ml. Also, they positively influenced the efficacy of fungicides. The mean MIC value (mean ± SD) for combination of all three fungicides with green AgNPs was 1.37 ± 0.6 µg/ml and for chemical AgNPs was 1.73 ± 1.0 µg/ml. Hence, it could be concluded that green AgNPs performed better than chemical AgNPs. Synergy was observed between green AgNPs and fungicides against Fusarium oxysporum. In conclusion, this study reports synthesis of monodisperse silver nanoparticles which serve as efficient antifungal agents and also enhance the fungicidal action of reported agricultural fungicides in combination studies.Inspec keywords: X‐ray diffraction, reduction (chemical), visible spectra, ultraviolet spectra, microorganisms, particle size, nanomedicine, nanofabrication, nanoparticles, agrochemicals, antibacterial activity, transmission electron microscopy, silver, light scattering, scanning electron microscopyOther keywords: antifungal effect, green silver nanoparticles, chemically synthesised silver nanoparticles, carbendazim, mancozeb, thiram, antifungal efficacy, common agricultural fungicides, biological reduction methods, chemical reduction methods, transmission electron microscopy, XRD assigned particles size, chemical silver nanoparticles, green AgNPs, chemical AgNPs, monodisperse silver nanoparticles, antifungal activity, agricultural fungicides, Elettaria cardamomum leaf extract, sodium citrate, UV‐visible spectroscopy, X‐ray diffraction, dynamic light scattering, size 31.86 nm, size 41.91 nm